Acticlate is a doxycycline hyclate prescription product family that illustrates why a brand name alone is not a complete pharmacy specification. U.S. labeling identifies Acticlate tablets at 75 mg and 150 mg and a separate Acticlate CAP 75 mg capsule. The word CAP is tied to the dosage form, not merely a marketing variation.
The Acticlate 150 mg tablet is functionally scored into three equal portions under the product-specific labeling; Acticlate CAP is a capsule that must be swallowed whole. These are prescription and dispensing distinctions, not permission to divide any doxycycline tablet or substitute a capsule for a tablet without pharmacist and prescriber review.
This article covers the Acticlate brand as a whole. Strength-specific searches belong to the 75 mg comparison and the 150 mg tablet guide.
Official FDA labeling distinguishes Acticlate tablets from Acticlate CAP capsules. Both contain doxycycline hyclate, but they are separately described dosage forms.
If a pharmacy listing shortens both to “Acticlate 75 mg,” it has omitted information needed for a precise match. Ask to see or hear the complete label designation before accepting the product.
The product family includes the 75 mg tablet, 150 mg tablet and 75 mg capsule. The strength number identifies the individual unit, not the appropriate use or dosing interval.
Patients should not switch among these items on the basis of perceived convenience. Each prescription must be interpreted by a licensed professional with the intended formulation in view.
The complete 2025 FDA prescribing information describes the Acticlate 150 mg tablet as functionally scored into three equal portions. Each third corresponds to 50 mg of doxycycline. Its specific scoring should not be generalized to different doxycycline tablet brands, especially modified-release formulations.
The detailed Dosage and Administration instructions in the FDA-approved labeling are the correct reference for this specific scoring design. A summary bullet or product photograph is not enough to decide how to handle a tablet. Patients should not divide the tablet unless the prescriber and dispensing pharmacist have explicitly confirmed the correct portion and instructions.
The labeled entries identify different strengths and forms, not patient-selected treatment options.
| Product | Strength and form | Distinctive note |
|---|---|---|
| Acticlate | 75 mg hyclate tablet | Tablet product identification |
| Acticlate | 150 mg hyclate tablet | Functionally scored design described in labeling |
| Acticlate CAP | 75 mg hyclate capsule | Separate capsule product name |
| Other doxycycline brands | Different salt or release technology possible | Do not infer equivalence from the ingredient alone |
The FDA has published updated Acticlate/Acticlate CAP prescribing information, including warnings and precautions. A long-lived commercial page should be anchored in the current product information rather than an old retailer description.
The presence of an approved label establishes the regulatory source for product details, not a guarantee that every strength is available at a nearby pharmacy.
Both are doxycycline hyclate products, but Doryx MPC is a distinct delayed-release tablet formulation with separate bioavailability and substitution warnings. The Acticlate strength and scoring features do not establish exchangeability with that product.
If delayed-release technology is mentioned on an alternative listing, consult the release-form overview before interpreting the offer.
An Acticlate tablet quote and an Acticlate CAP quote may differ by package, form and insurance treatment. Comparing them as if they were a single 75 mg item can misrepresent out-of-pocket costs.
A licensed pharmacist should confirm the prescribed form, approved alternative if proposed, quantity and applicable coverage. This brand page does not rank sellers or imply current discounts.
Before taking the medicine, review the product-specific administration directions, tetracycline allergy history, concurrent medications, photosensitivity and clinically significant adverse-effect warnings.
If the dispensed item is unexpectedly a capsule instead of a tablet, resolve the discrepancy immediately. For general substitution concepts beyond Acticlate, visit the generic doxycycline guide.
A brand family of oral doxycycline hyclate tablets, with a related Acticlate CAP capsule product.
No. Acticlate CAP 75 mg is a doxycycline hyclate capsule.
The U.S. labeling identifies 75 mg and 150 mg tablets.
It has product-specific functional scoring; follow the actual prescription and pharmacist guidance.
No. Doryx MPC is a distinct delayed-release formulation.
Yes. FDA published Acticlate and Acticlate CAP labeling with changes in 2025.
No. Availability must be verified for the exact form and strength at a licensed pharmacy.